Engflag

Tacroz

Quick links to important sections

Tacroz

Tacroz_ES

Method of action: Calcineurin Inhibitory, Dermatotropic, Immunosuppressive, Other Dermatological Preparations

Treatment option: Dermatitis, Kidney Transplant

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tacroz

Property Description
Active ingredient Tacrolimus
Form Topical Ointment (e.g., 0.03% or 0.1%)
Pharmacological class Calcineurin Inhibitor
Common use Treatment of inflammatory skin conditions
Origin Derived from the macrolide antibiotic FK-506

Tacroz is a prescription topical ointment whose active ingredient is tacrolimus. Tacrolimus is categorized as a calcineurin inhibitor, an advanced type of immunomodulator. This drug is primarily used in dermatology to address the underlying inflammation responsible for various chronic skin conditions. The medication works locally by selectively modifying the immune response in the skin.

The active ingredient, tacrolimus, has a unique origin, deriving from the naturally occurring macrolide antibiotic FK-506. It was first approved for topical use in the United States in 2000. Tacroz is a brand-specific formulation of this drug, manufactured in different concentrations, such as the lower-strength 0.03% and the higher-strength 0.1%, allowing for therapy to be tailored to the patient’s needs and the severity of the condition.

Tacroz is often used as a non-corticosteroid option, making it a valuable alternative for long-term topical therapy, especially when treating sensitive areas of the body. Its use is clinically recognized for its effectiveness in modulating key inflammatory pathways, offering patients a way to control symptoms without relying on steroid products. As it is prescription-only, a healthcare provider must assess the patient's condition to determine the appropriate concentration and duration of use.

Regulatory References

  1. National Institutes of Health

What side effects are possible with Tacroz?

Possible Side Effects and Safety Information

The safety profile for Tacroz (tacrolimus topical) is based on data from official regulatory documents and is structured around the frequency and nature of documented adverse reactions.

Common Adverse Reactions

The most frequently reported side effects are localized to the application site. These reactions are typically mild to moderate and often lessen after the first week of use. They are classified according to regulatory frequency standards:

  • Very Common (Affects 1 in 10 or more): Application site burning.
  • Common (Affects up to 1 in 10): Application site pruritus (itching), erythema (redness), skin irritation, folliculitis, headache, and alcohol intolerance (facial flushing or irritation).

Other commonly affected body systems include the Integumentary System (skin and subcutaneous tissue disorders) and the Nervous System.

Serious Adverse Reactions and Restrictions

Official regulatory labeling includes warnings about rare but serious adverse reactions. The product label contains a warning regarding an association with rare cases of malignancies, including lymphoma and skin cancer. Patients must avoid excessive exposure to natural or artificial sunlight (UV light) during treatment.

Tacroz ointment should not be applied to areas of broken, cut, or infected skin and the use of occlusive dressings is not recommended.

Population-Specific Safety

  • Pediatric Use: The medication is not approved for use in children under 2 years of age. The 0.1% strength is not recommended for pediatric patients (ages 2–16).
  • Pregnancy and Lactation: Use is generally contraindicated during pregnancy and breastfeeding, as safety has not been fully established, and the drug is excreted in human milk.

Overdose and Emergency Response

Overdose Scope

Documented overdose presentations:

  • Symptoms from the topical ointment formulation are not specifically documented in regulatory labels due to minimal systemic absorption; severe systemic toxicity data are primarily relevant to accidental oral ingestion.

Physiological systems affected (as stated in label):

  • Systems potentially affected by serious overdose relate to systemic toxicity, notably the central nervous system (seizure, unresponsiveness) and respiratory system (trouble breathing).

Dose-related or exposure-related factors (if applicable):

  • The main overdose circumstance addressed in regulatory labeling is accidental oral ingestion of the ointment.

Population-specific overdose notes (if applicable):

  • No specific population-based considerations (e.g., pediatric, renal impairment) regarding the severity or management of topical ointment overdose are explicitly detailed in the official overdose sections.

Emergency-response statements (as written in official documents):

  • Management consists of symptomatic and supportive treatment.
  • Gastric lavage may be considered for recent ingestion to remove non-absorbed drug.
  • Hemodialysis is not expected to be effective in clearing the drug.

When immediate medical help is required (label-derived phrasing only):

  • Seek immediate medical attention for cases of accidental oral ingestion of the ointment.
  • Contact a Poison Control center or call emergency services immediately when severe symptoms, such as collapse, seizure, or trouble breathing, are present.

Overdose Classifications (High-Level)

Severity classification (as defined in official documents):

  • Severity is implicitly defined by the mandatory requirement for immediate medical intervention following accidental ingestion.

Regulatory basis (EMA / FDA / etc.):

  • FDA Prescribing Information / NIH DailyMed / NIH MedlinePlus.

Overdose-context constraints (as defined in official documents):

  • No specific antidote is known for tacrolimus overdose.

Resulting Overdose Structure

Official overdose statements:

  • Accidental oral ingestion of the ointment requires immediate medical attention.
  • No specific antidote is known, and management should consist of symptomatic and supportive treatment.
  • Urgent help is mandated if symptoms include seizure, collapse, or trouble breathing.
  • Due to the drug's properties, hemodialysis is not expected to be effective for clearance following overdose.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile by focusing on the high-risk scenario of accidental oral ingestion, which necessitates immediate medical intervention, including contacting emergency services or a Poison Control center. This response is structured around providing supportive care, as the label states that no specific antidote is known and standard drug removal methods like hemodialysis are ineffective. The official guidance mandates that urgent help must be sought when the ingestion victim exhibits severe symptoms such as unresponsiveness or seizure, aligning with the highest level of risk.

Therapeutic Uses of Tacroz

What Tacroz Treats: Main Uses and Benefits

Tacroz is commonly used across conditions presenting with acute or episodic symptom patterns, primarily providing supportive relief for inflammatory skin disorders. The ointment is indicated for the treatment of moderate to severe Atopic Dermatitis (eczema) in adults and children aged two years and older.

Symptom Relief and Therapeutic Context

Tacroz is relevant for easing symptoms related to inflammatory or irritative states and is used for managing groups of symptoms that may become intense or disruptive. The primary focus is on managing symptoms that include severe pruritus (intense itching), visible skin redness, and active eczematous lesions. It is often used during phases when symptoms become more noticeable, particularly for treatment on sensitive body regions. The medication supports the management of symptoms without using corticosteroids, aligning with domains involving significant symptom expression.

“The treatment is generally considered relevant in conditions presenting with systemic or localized discomfort, contributing to easing the overall symptom load.”

This application is commonly used when symptoms intensify, and supportive relief is needed. This option provides supportive relief when symptoms interfere with routine activities, contributing to easing the overall symptom load and helping maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Symptomatic Relief for Severe Itching (Pruritus) Tacroz is commonly used to help with symptoms related to inflammatory or irritative states.

Eligibility and Restrictions for Use

Official Eligibility Rules for Tacrolimus Ointment

Regulatory agencies define specific population eligibility rules for tacrolimus topical ointment, structuring who is permitted to use the medicine and who is prohibited.

Eligibility scope Official Regulatory Status
Populations for whom use is allowed Adults and adolescents (16 years and older) may use both the 0.03% and 0.1% strengths. Children aged 2 to 15 years are restricted to the 0.03% strength only.
Populations for whom use is contraindicated Patients with a history of hypersensitivity to tacrolimus, other macrolides, or any component of the ointment. Use is contraindicated in children younger than two years of age.
Populations for whom use is not recommended Not recommended for patients with congenital or acquired immunodeficiencies. Use is also not recommended in individuals with skin barrier defects like Netherton’s Syndrome due to risk of increased systemic absorption.
Pregnancy and lactation eligibility Should not be used during pregnancy unless clearly necessary. Use is not recommended in nursing mothers.

Eligibility is also defined by context, limiting use to second-line therapy and restricting continuous long-term application. The ointment must be used with caution in patients with severe hepatic impairment and should not be applied to areas with active skin infections.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The official interaction profile for Tacroz (tacrolimus topical ointment) focuses on specific cautionary uses and product separation requirements, due to the minimal systemic absorption typically observed with topical administration.

Official Interaction Statements

  • CYP3A4 Inhibitors: The concomitant use of known CYP3A4 inhibitors is advised with caution in patients with widespread and/or erythrodermic disease. This cautionary restriction addresses the potential for increased systemic exposure of tacrolimus in patients where the skin barrier is significantly compromised. Examples of substances cited in regulatory documents include Erythromycin, Itraconazole, Ketoconazole, Fluconazole, and Cimetidine.
  • Alcohol: Drinking alcohol may cause a localized flushing or redness and warmth of the skin or face (a vasomotor reaction) while using the ointment.
  • Emollients: A mandatory separation window exists: Emollients should not be applied to the same area within 2 hours of applying Tacroz ointment.

Population-Specific Interaction Notes

Tacroz should be used with caution in patients with hepatic failure due to the drug’s metabolic route. Patients with skin conditions that greatly increase systemic absorption, such as generalized erythroderma or Netherton’s syndrome, have a higher risk of systemic drug interactions and require careful monitoring.

Mechanism of Action

How Tacroz Works — Mechanism of Action

The mechanism of action of tacrolimus (the active ingredient in Tacroz) is characterized by specificity for defined molecular pathways, focusing on molecular pathways to modulate the immune response within the skin.

Inhibiting Calcineurin to Suppress T-Cell Signaling

Tacrolimus acts by first binding to the intracellular protein FKBP12, forming a complex that functions as a non-competitive inhibitor of the enzyme calcineurin. This inhibition prevents calcineurin from activating the transcription factor NFAT, which is essential for initiating T-lymphocyte proliferation and function. This molecular cascade directly and rapidly suppresses the synthesis of pro-inflammatory cytokines, such as Interleukin-2 (IL-2), resulting in a reduction of the localized immune response.

️ Local Mediator Modulation and Sensory Influence

Beyond T-cell suppression, tacrolimus modulates other inflammatory and sensory systems. It results in decreased release of pre-formed inflammatory mediators like histamine by stabilizing cutaneous mast cells. Furthermore, the drug influences sensory nerves in the skin, modulating the activity of receptors like TRPV1 that are involved in neurogenic inflammation and itch (pruritus). This dual action—immune suppression combined with sensory nerve modulation—results in the modulation of the local tissue environment and modifies the effects associated with excessive mediator activity.

Dosage and Administration Information

How to Use Tacroz

Tacroz (tacrolimus) is a prescription medication administered strictly via the topical route as an ointment for external use on the skin. Its application is organized into two primary patterns: a higher-frequency regimen for active flares and a lower-frequency schedule for maintenance, reflecting its use as an intermittent short-term and long-term therapy.

Official Administration Guidelines

Administration Scope Detail
Route of administration Topical (external use on the skin only).
Dosing Schedule (Flares) Applied twice daily (BID) until the skin lesion is cleared or almost cleared.
Dosing Schedule (Maintenance) Applied twice weekly to previously affected areas to prevent relapse.
Age-Group Rules Adults/Adolescents (≥ 16 years): May use 0.03% or 0.1% strength.
Pediatric (2 to 15 years): Use is limited to the lower 0.03% strength only.

Procedural Instructions

For proper administration, only a thin layer of the ointment should be applied to the affected areas. It is an explicit procedural restriction that treated skin must not be covered with occlusive dressings, bandages, or wraps. Treatment for flares is to be discontinued once symptoms resolve, with re-initiation only required at the first signs of recurrence. If a dose is missed, it should be applied as soon as it is remembered, with the regular dosing schedule resumed thereafter.

Recent Clinical Evidence

Tacroz: Recent Clinical Evidence

Evidence Base for Moderate to Severe Atopic Dermatitis (Eczema)

Research on Tacroz has centered extensively on its FDA-approved use and was studied for moderate to severe Atopic Dermatitis (eczema). The evidence base primarily consists of short-term randomized controlled trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms typical of the condition. Researchers used the studies to monitor symptom patterns over defined time intervals, and the evidence contributes to understanding the condition in a research setting.

In these trials, findings describe patterns observed in the studies related to specific, measured outcomes. Studies examined whether symptoms evolved in the observed populations by using standard severity scales, such as the Eczema Area and Severity Index (EASI). Research also examined patient-reported outcomes describing perceived discomfort, focusing on the intensity of pruritus (intense itching).

Evidence in Specific Patient Populations: Children and Adults

Tacroz was evaluated in both adults (aged 16 and older) and pediatric patients (children aged 2 to 15) with moderate to severe Atopic Dermatitis. Studies for these groups were conducted separately, including outcomes relevant to conditions involving periods of heightened symptoms in each age cohort. Research highlights changes measured during the study period for both groups. However, certainty remains low regarding the direct comparability of long-term outcomes between the two age groups.

Long-Term Follow-up and Evidence Gaps

Research explored the use of Tacroz beyond the initial treatment phase. Studies monitored patients over defined time intervals that included intermediate (6–12 months) and longer periods. For the purpose of gathering comprehensive data, extended post-marketing surveillance studies exist, with research ongoing for up to 10 years. Despite the existence of these long-term observational settings, limited information is available for fully establishing the long-term effects. Comparative evidence is lacking when looking at the full spectrum of available topical options.

Key Studies & References Tacrolimus - Calcineurin Inhibitor Pharmacology and Mechanism of Action (National Institutes of Health - NCBI Bookshelf)

How should Tacroz be stored and disposed of?

How to Store and Dispose of Tacroz?

To ensure product stability, Tacroz ointment must be stored at room temperature, specifically between 20 and 25 C (68 and 77 F), with permitted temperature excursions up to 30 C (86 F). The product must be protected from both excessive heat and moisture.

Always store the ointment in its original container and keep the tube tightly closed when it is not being used. For safety, the medication must be kept out of the reach of children.

When disposing of unused, expired, or no-longer-needed ointment, the official guidance is to utilize a community medicine take-back program. If such a program is not available, the ointment should be mixed with an undesirable substance, sealed in a bag or container, and discarded in the household trash. Do not flush the medication down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagEcuador

flagIndia

flagPeru

flagVietnam

Equivalent of Tacroz found in:

A-Z Index: